Sentences with phrase «year revenue growth rate»

- Seven Year Revenue Growth Rate: 10.5 % Dividend Stock Report - Seven Year EPS Growth Rate: 7.3 % - Seven Year Dividend Growth Rate: 11.2 % - Current Dividend Yield: 2.84 % - Balance Sheet: Stable

- Seven Year Revenue Growth Rate: 5.8 % - Seven Year EPS Growth Rate: 9.4 % - Seven Year Dividend Growth Rate: 14.9 % - Current Dividend Yield: 2.43 % - Balance Sheet: Reasonable Leverage, Stable Currently, Walmart's $ 77 share price appears to be fairly valued for an expectation of 10 % long - term returns.

It launched in 2011 and has a three - year revenue growth rate of 743 %.

In 2015, the company topped Deloitte's Canadian Technology Fast 50, with a four - year revenue growth rate of 18,480 %.

In return, those companies helped Lynx break into the top 100 of this year's Inc. 5000 for the first time, with three - year revenue growth rate of 3,740 percent.

Not exact matches

Tesla took a positive outlook for 2018, saying that «the planned ramp of both Model 3 and our energy storage products, our rate of revenue growth this year is poised to significantly exceed last year's growth rate.»

Financial services company Balyasny Europe Asset Management performed best, with a three - year growth rate of 3,469 percent and $ 39.4 million in revenue in 2015.

The program, now in its 20th year, ranks companies based on their «entrepreneurial spirit, innovation, rapid revenue growth, and world - class achievements» over the preceding four years, with growth rate being the key consideration for where companies rank on the list.

IBISWorld provided detailed past industry growth percentages, revenue forecasts for the next five years, employment growth, profit margin averages, and industry competition ratings.

Outdoor Tech has a three - year growth rate of 1,869 percent and 2014 revenue of $ 8.3 million.

At No. 42 on this year's Inc. 5000, the tablet and computer maker for companies such as Groupon and LivingSocial has a three - year growth rate of 5,866 percent and 2014 revenue north of $ 6 million.

Rates of employment and revenue growth were higher in the program's business «clusters» than in comparable numbers of unaffiliated businesses, according to analysis of the SBA's two - year pilot Regional Cluster Initiative.

Proving that all work doesn't mean no play, trampoline park creators Sky Zone lands the no. 273 spot on this year's Inc. 5000, with 2014 revenue of $ 24.4 million and a three - year growth rate of 1,674 percent.

3 - Year Growth Rate: 10,372 % 2013 Revenue: $ 34.4 million Inc. 5000 Rank: No. 22 The Richmond, Virginia - based frozen yogurt chain sweetFrog was founded by Derek Cha in 2009.

Bisnow has not disclosed its revenue, but in 2013, it had $ 13.8 million in sales with a three - year growth rate of 258 %, according to Crain's New York.

At No. 150, the recently acquired Midroll Media has a three - year growth rate of 2,616 percent and a 2014 revenue of more than $ 7.9 million.

Barnett Waddingham, a consulting and actuarial services firm, leads the pack, with a three - year growth rate of 1,167 percent and $ 43 million in revenue in 2014.

China's box office revenue is still swelling at double - digit rates after years of breakneck growth and, with Hollywood know - how and bigger budgets, Chinese movies are gaining momentum as they find ways to play on domestic themes and improve production quality.

The Honest Kitchen has achieved a 30 percent year - over-year revenue growth rate in 14 years in the pet food market.

With $ 23 million in revenue in 2011, a three - year growth rate of 10,160 %, and over $ 40 million in investments, Nasty Gal's Sophia Amoruso is feeling lucky.

Founded in 2007, Maxprofit Trade brought in $ 15.3 million ($ 16.4 million) in revenue in 2013, giving it a 1,038 percent three - year growth rate.

The company has also added more than 30,000 new customers in its DSS division so far this year, 42 % above the average growth rate, which will give revenue a boost.

If that growth rate continues, the U.S. industry will increase its revenues for the second year in a row — the first time it has had back - to - back growth years since CD sales hit their peak in 1999.

This year's list is the product of old - fashioned reporting, boosted by data and insight supplied by a trio of independent research firms: Sageworks, which performs financial analyses of privately held companies; Plunkett Research, a business intelligence firm that studies trends affecting the world's most vital industries; and IBISWorld, which provides industry growth figures, five - year revenue projections, employment growth, profit margin averages, and industry competition ratings.

Optiva topped the Inc. 5000 in 1997 with a five - year growth rate of 31,507 percent and revenue of more than $ 72 million.

The Conservatives program review this year will close the gap in expected revenue and spending growth somewhat but will still depend on rather dramatic growth rates in tax revenues.

In the base year used in the five - year growth calculation (e.g., 2012), any companies with revenue of less than $ 200,000 will have their revenue for that period lifted to $ 200,000 for the purpose of calculating five - year growth that is not grossly exaggerated by immaterial differences in the base - year revenues of otherwise equal candidates (for instance, a company that grows from $ 1 to $ 2 million would have a higher growth rate than a company that grows from $ 2 to $ 3 million).

Companies that meet these criteria are ranked by revenue growth rate, EPS growth rate, and three - year annualized total return for the period ended June 30, 2017.

VCs were crawling over themselves to grab a bite of Databricks for a one main reason: In just four years, Databricks had already amassed about 500 big companies as customers, so revenue was growing, Ghodsi said, although he wouldn't indicate how much revenue the company had generated or its growth rate.

In the base year used in the two - year growth calculation (e.g., 2015), any companies with revenue of less than $ 200,000 will have their revenue for that period lifted to $ 200,000 for the purpose of calculating two - year growth that is not grossly exaggerated by immaterial differences in the base - year revenues of otherwise equal candidates (for instance, a company that grows from $ 1 to $ 2 million would have a higher growth rate than a company that grows from $ 2 to $ 3 million).

With a three - year growth rate of more than 4,000 percent, this data collection company, which works with businesses and law firms, reeled in more than $ 4 million in revenue in 2014.

Without it, however, AECOM's organic revenue growth was flat last year, restrained in part by the effects of currency - exchange rates.

Greenspire has a 14,429 % three - year growth rate and made $ 41.7 million in revenue in 2016.

It expects full - year organic revenue growth of at least 2.3 percent — its 2017 growth rate.

In its first three years, RevolutionParts (No. 692) had a revenue growth rate of 655 %, earning $ 3.4 million in 2016.

When employee - engagement firm TinyPulse combed through staffer - happiness surveys, it found that roughly 70 percent of startups hit a rough patch around year three or four — and companies with higher revenue - growth rates had deeper problems.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Yet when we went out to fund raise this year after 4 years of a 200 percent revenue CAGR (compounded annual growth rate) the first firm that we spoke with said,

For the company's first seven years, he served as CEO, growing Vitals.com to over 10 million monthly visitors and a 65 percent compounded annual revenue growth rate.

Commentary: «Revenues were up 8.3 % for the third quarter versus the prior - year period, due primarily to higher commodity prices impacting the Company's supply chain revenues, higher same store sales in both domestic and international stores, store count growth in international markets and the positive impact of changes in foreign currency exchange ratesRevenues were up 8.3 % for the third quarter versus the prior - year period, due primarily to higher commodity prices impacting the Company's supply chain revenues, higher same store sales in both domestic and international stores, store count growth in international markets and the positive impact of changes in foreign currency exchange ratesrevenues, higher same store sales in both domestic and international stores, store count growth in international markets and the positive impact of changes in foreign currency exchange rates.»

According to a recent Morgan Stanley Research report, U.S. commercial real - estate pricing in 2017 could drop by as much as 10 %, year over year, amid slowing revenue growth, rising interest rates and tightening lending conditions.

Maybe the equity isn't growing exactly at the same rate as revenue growth, but it's certainly growing faster than 15 % a year.

Forward - looking statements may include, among others, statements concerning our projected adjusted income (loss) from operations outlook for 2018, on both a consolidated and segment basis; projected total revenue growth and global medical customer growth, each over year end 2017; projected growth beyond 2018; projected medical care and operating expense ratios and medical cost trends; our projected consolidated adjusted tax rate; future financial or operating performance, including our ability to deliver personalized and innovative solutions for our customers and clients; future growth, business strategy, strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; the proposed merger (the «Merger») with Express Scripts Holding Company («Express Scripts») and other statements regarding Cigna's future beliefs, expectations, plans, intentions, financial condition or performance.

Within budgetary revenues, personal income tax revenues were up $ 7.7 billion (6.1 %), slightly above the growth rate forecast in the 2018 Budget for the year as a whole.

In fiscal» 12, our revenues reached $ 24.1 billion; that's up 16 %, our highest growth rate in 15 years.

Syria, Russia say Israel launched missile strike on Syrian air base Wall St Journal Hungary's nationalist prime minister wins third term in power: Reuters Trump predicts China will blink first in trade dispute with US: Bloomberg Trump administration officials soften tone on trade dispute with China: WSJ N. Korea says it will discuss denuclearization: NY Times Kudlow: White House considering plans to undo parts of spending bill: Wash Exam US hiring growth slowed sharply in March: Bloomberg German industrial production fell by the most in over 2 years in Feb: Reuters Forward curve for 1 month overnight indexed swap rate inverts: Bloomberg Many US state govts struggling with weak revenue growth: The Economist

For example, the year - over-year increases in corporate income taxes and GST revenues are well above the growth rates in their respective tax bases, which could be attributable to changes in the accrual adjustment ratios.

Even if the growth rates of nominal GDP and U.S. corporate revenues (including foreign revenues) over the coming 20 years match their 4 % growth rate of the past 20 years, and even if the most reliable valuation measures merely touch their historical norms 20 years from today, the S&P 500 Index two decades from now will trade more than 20 % lower than where it trades today.

To project future years, the average growth rate for child benefits in recent years was used, based on historical data from Canada Revenue Agency (CRA) and the Public Accounts.

I find it awfully hard to believe that WDAY can continue its high rate of revenue growth for another 10 years.